An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Forigerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Registrational
- Acronyms IP-006
- Sponsors ImmuPharma
- 28 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
- 28 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Feb 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.